Jacob Asset Management of New York’s Arcturus Therapeutics ARCT Stock Holding History

Jacob Asset Management of New York’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$196K	Sell	7,677 -2,400	-24%	-$73.9K	0.28%	55
2023 Q2	$289K	Sell	10,077 -2,334	-19%	-$63.5K	0.33%	55
2023 Q1	$297K	Sell	12,411 -2,110	-15%	-$37.9K	0.35%	50
2022 Q4	$246K	Sell	14,521 -6,395	-31%	-$112K	0.3%	51
2022 Q3	$310K	Buy	20,916 +41	+0.2%	+$688	0.34%	49
2022 Q2	$329K	Sell	20,875 -4,040	-16%	-$79.3K	0.33%	51
2022 Q1	$672K	Sell	24,915 -5,406	-18%	-$138K	0.41%	48
2021 Q4	$1.12M	Sell	30,321 -25,834	-46%	-$1.05M	0.5%	45
2021 Q3	$2.68M	Buy	56,155 +5,155	+10%	+$231K	0.98%	31
2021 Q2	$1.73M	Buy	51,000 +26,000	+104%	+$880K	0.57%	45
2021 Q1	$1.03M	Buy	25,000 +9,800	+64%	+$584K	0.4%	57
2020 Q4	$659K	Buy	+15,200	New	+$1.03M	0.5%	42

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacob Asset Management of New York's ARCT Position: Q3 2023 in Review

Jacob Asset Management of New York reduced its Arcturus Therapeutics (ARCT) stake by 24% in Q3 2023, selling an estimated $73.9K and leaving 7,677 shares worth $196K. The position accounts for 0.28% of the portfolio, ranked #55.

Jacob Asset Management of New York first reported a position in ARCT in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.68M in Q3 2021. 145 funds tracked by Wall St. Rank hold ARCT as of Q3 2023.

Jacob Asset Management of New York held 7,677 shares of Arcturus Therapeutics worth $196K as of Q3 2023.
Jacob Asset Management of New York sold 2,400 Arcturus Therapeutics shares in Q3 2023, an estimated $73.9K.
Arcturus Therapeutics made up 0.28% of Jacob Asset Management of New York's portfolio in Q3 2023, its #55 holding.
Jacob Asset Management of New York first reported a position in Arcturus Therapeutics in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's Arcturus Therapeutics position peaked at $2.68M in Q3 2021.
145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.